Phase 2 study of neoadjuvant tri-weekly Nab-paclitaxel and Trastuzumab followed by FEC(5-FU/epirubicin/cyclophosphamide) in patients for HER2 positive breast cancer. - Phase 2 study of neoadjuvant tri-weekly Nab-paclitaxel and Trastuzumab followed by FEC(5-FU/epirubicin/cyclophosphamide) in patients for HER2 positive breast cancer.

Department of gastroenterologic and breast surgery Kanazawa University,School of Medicine0 个研究点目标入组 35 人开始时间: 2013年4月30日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Allergy of the nab-Paclitaxel, Epirubicin,Cyclophosphamide and Fluorouracil 2) Active secondary malignancies 3) Bilateral invasive breast cancer 4) Severe complications (infection, diarrhea, paresis of intestine, obstruction of the intestines, uncontrolled diabetes mellitus, etc.) 5) Positive for HBs antigen and the history of HBV infection 6) Severe heart disease, or the patient who has past history of it 7) Severe mental disease or under treatment 8) Active gastrointestinal tract ulcer or bleeding 9) Severe bone marrow suppression, renal dysfunction, and liver dysfunction 10) Severe pleural effusion or ascites 12) Pregnancy or suspected pregnancy 13) Physician judged improper to entry this trial

发起方

Department of gastroenterologic and breast surgery Kanazawa University,School of Medicine